Newly Established Specialty Pharmaceuticals Company Investment Opportunity in Los Angeles, United States

- Drug reformulation pharmaceutical company based in Los Angeles.

- Focused on developing drugs through Phase I to IV to achieve FDA approval.

- Primarily directed towards improving health outcomes in the neurosciences and beyond.

- Dedicated to finding innovative and effective treatment solutions to the most challenging ailments related to the Central Nervous System.

- This is done by transforming positive clinical results from decades of hands-on patient care experience into rigorous scientific research.

- The company has 10 patented products in its portfolio, some of which have the potential to generate annual revenues ranging from $200 million to $1 billion per product.

- 4 of these products need to be moved to Phase IIb.

- The products cater to critical healthcare needs in America and are planned to be established through publication on popular channels to showcase the efficacy.

- Also has a network of 70,000 pharmacies, providing a robust distribution platform for its products.

- While the company owns the formulation of its products, the production is outsourced through external laboratories.

- Led by 8 partners with over 100 years of combined professional experience in patient care, clinical research, and entrepreneurship. They bring vast experience in CNS-related drug development, ensuring a strong foundation for the company's operations.

Drug combinations for treatment of ailments related to the Central Nervous System.

Planning to establish by through publications on popular channels to showcase the efficacy and supply to pharmacies.

No physical assets of significant value.

Intangible assets include the patents for 10 products under development.

Operating from a rented office space at Wells Fargo building in downtown LA.

Business have not received external funding.

Self-funded with $400,000 till date.

Current shareholders are 8 founding partners.